Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer

Gynecologic Oncology

Volumn 126, Issue 1, 2012, Pages 47-53

  Fu, Siqing ^a   Hennessy, Bryan T ^a,b   Ng, Chaan S ^a   Ju, Zhenlin ^a   Coombes, Kevin R ^a   Wolf, Judith K ^a   Sood, Anil K ^a   Levenback, Charles F ^a   Coleman, Robert L ^a   Kavanagh, John J ^a   Gershenson, David M ^a   Markman, Maurie ^a   Dice, Kristine ^a   Howard, Adrienne ^a   Li, Jane ^a   Li, Yang ^a   Stemke Hale, Katherine ^a   Dyer, Mary ^a   Atkinson, Edward ^a   Jackson, Ed ^a   Kundra, Vikas ^a   Kurzrock, Razelle ^a   Bast Jr , Robert C ^a   Mills, Gordon B ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

AKT; Docetaxel; Epithelial ovarian cancer; Perfosine; Platinum resistance; Taxane resistance

Indexed keywords

DOCETAXEL; FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; FATIGUE; HUMAN; HUMAN TISSUE; INFECTION; INTESTINE OBSTRUCTION; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE SCANNER; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR BIOPSY; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PHOSPHORYLCHOLINE; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TAXOIDS;

EID: 84862773728     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.04.006     Document Type: Article

References (50)

1. Franke TF. PI3K/Akt: getting it right matters. Oncogene 2008;27:6473-88.
2. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
3. Kolasa IK, Rembiszewska A, Felisiak A, et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 2009;8:21-6.
4. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
5. Willner J, Wurz K, Allison KH, et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 2007;38:607-13. (Pubitemid 46399888)
6. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174:1597-601.
7. Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2:1093-103.
8. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107:4053-62. (Pubitemid 43726814)
9. Unger C, BerdelW,Hanauske AR, et al. First-time-in-man and pharmacokinetic study ofweekly oral perifosine in patientswith solid tumours. Eur J Cancer 2010;46:920-5.
10. Leighl NB, Dent S, Clemons M, et al. A phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat 2008;108:87-92. (Pubitemid 351623244)
11. Marsh Rde W, Rocha Lima CM, Levy DE, et al. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2007;30:26-31. (Pubitemid 46213821)
12. Bailey HH, Mahoney MR, Ettinger DS, et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 2006;107:2462-7. (Pubitemid 44748530)
13. Argiris A, Cohen E, Karrison T, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006;5:766-70. (Pubitemid 44775131)
14. Knowling M, Blackstein M, Tozer R, et al. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2006;24:435-9. (Pubitemid 43876080)
15. Posadas EM, Gulley J, Arlen PM, et al. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 2005;4:1133-7. (Pubitemid 41598570)
16. Ernst DS, Eisenhauer E, Wainman N, et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 2005;23:569-75. (Pubitemid 43162477)
17. Van Ummersen L, Binger K, Volkman J, et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004;10:7450-6. (Pubitemid 39557506)
18. Crul M, Rosing H, de Klerk GJ, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002;38:1615-21. (Pubitemid 34876501)
19. Pal SK, Reckamp K, Yu H, et al. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010;19:1355-66.
20. Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
21. Le XF, Hittelman WN, Liu J, et al. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 2003;22:484-97. (Pubitemid 36188606)
22. Hu L, Hofmann J, Lu Y, et al. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002;62:1087-92. (Pubitemid 34160292)
23. Hennessy BT, Lu Y, Poradosu E, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007;13:7421-31.
24. Fu S, Hu W, Iyer R, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011;117:1661-9.
25. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. (Pubitemid 36962641)
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
27. Rustin GJ, Nelstrop AE, Crawford M, et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 1997;15:172-6. (Pubitemid 27020570)
28. Huston A, Leleu X, Jia X, et al. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res 2008;14:865-74. (Pubitemid 351231171)
29. Carey MS, Agarwal R, Gilks B, et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 16:2852-60
30. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68:6084-91.
31. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347-51. (Pubitemid 46328493)
32. Jurinke C, van den Boom D, Cantor CR, et al. The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol 2002;77:57-74.
33. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82.
34. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23:5464-73.
35. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-9. (Pubitemid 29463107)
36. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000;18:2733-9. (Pubitemid 30463556)
37. Kavanagh JJ, Kudelka AP, de Leon CG, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837-42.
38. Markman M, Zanotti K, Webster K, et al. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol 2003;91:573-6. (Pubitemid 38388153)
39. Dong G, Chen Z, Li ZY, et al. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 2001;61:5911-8. (Pubitemid 32769111)
40. Xu L, Pathak PS, Fukumura D. Hypoxia-induced activation of p38 mitogenactivated protein kinase and phosphatidylinositol 3′-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res 2004;10:701-7. (Pubitemid 38174009)
41. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006;25:6986-96. (Pubitemid 44684839)
42. Birkenkamp KU, EsselinkMT, KruijerW, et al. An inhibitor of PI3-K differentially affects proliferation and IL-6 protein secretion in normal and leukemic myeloid cells depending on the stage of differentiation. Exp Hematol 2000;28:1239-49.
43. Medina EA, Morris IR, Berton MT. Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain. J Immunol 2010.
44. Rabot M, El Costa H, Polgar B, et al. CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. Int Immunol 2007;19:401-9. (Pubitemid 46523388)
45. Takai S, Tokuda H, Hanai Y, et al. Phosphatidylinositol 3-kinase/Akt plays a part in tumor necrosis factor-alpha-induced interleukin-6 synthesis in osteoblasts. Horm Metab Res 2006;38:563-9. (Pubitemid 44569139)
46. Mohseni M, Park BH. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001. J Clin Invest 2010;120:2655-8.
47. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011;10:558-65.
48. Kumar A, Lawrence Jr JC, Jung DY, et al. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 2010;59:1397-406.
49. Kumar A, Harris TE, Keller SR, et al. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances basal glycogen synthase activity. Mol Cell Biol 2008;28:61-70.
50. Ma WW, Jacene H, Song D, et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009;27:2697-704.